Leveraging Evolutionary Immunology in Interleukin-6 and Interleukin-17 Signaling for Lung Cancer Therapeutics DOI

Riya Khilwani,

Shailza Singh

ACS Pharmacology & Translational Science, Journal Year: 2024, Volume and Issue: 7(12), P. 3658 - 3670

Published: Nov. 22, 2024

Lung cancer is among the most common instances of subtypes and associated with high mortality rates. Due to availability fewer therapies delayed clinical investigations, number incidences rising dramatically. This possibly an effect immune modulations chemotherapeutic drugs that raises resistance. Among list, IL-6 IL-17 are host-derived paradoxical effectors attune responses in malignant lung cells. Their excessive release cytokine milieu stabilizes immunosuppressive phenotypes, resulting cellular perturbations. During tumor development, significance these molecules reflected their potential regulate oncogenesis by initiating a myriad signaling events influence growth metastatic ability benign Moreover, transactivation contributes antiapoptotic mechanisms favors cell survival via constitutive expression immunoregulatory molecules. Co-evolution gene duplication could be major drivers behind evolution, which have prompted generic changes and, hence, additive effect. The evolutionary model statistical analysis provide evidence about cytokines ancestral relationships site-specific conservation, more convincing as both share cysteine-knot-like structures important maintaining structural integrity. Funneling through findings help find residues serve catalytic role functioning. Designing peptides or subunit vaccine formulations against those conserved aid combating pathogenesis.

Language: Английский

Exploring the mechanism and crosstalk between IL-6 and IL- 1β on M2 macrophages under metabolic stress conditions DOI

Shawna Yadav,

Anusha Prasannan,

Kaliyamurthi Venkatachalam

et al.

Cytokine, Journal Year: 2025, Volume and Issue: 186, P. 156852 - 156852

Published: Jan. 6, 2025

Language: Английский

Citations

1
Unveiling the orchestration of T-cell dynamics: A comprehensive examination of their crucial role in revolutionizing immunotherapy for pancreatic and colon cancers DOI

Sridevi Mardham,

Soumya Dakshinamurthy

Elsevier eBooks, Journal Year: 2025, Volume and Issue: unknown, P. 199 - 232

Published: Jan. 1, 2025

Language: Английский

Citations

0
Innate Immune Response and Epigenetic Regulation: A Closely Intertwined Tale in Inflammation DOI

Diksha Jawale,

Shweta Khandibharad,

Shailza Singh

et al.

Advanced Biology, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 12, 2024

Maintenance of delicate homeostasis is very important in various diseases because it ensures appropriate immune surveillance against pathogens and prevents excessive inflammation. In a disturbed homeostatic condition, hyperactivation cells takes place interplay between these triggers plethora signaling pathways, releasing pro-inflammatory cytokines such as Tumor necrosis factor alpha (TNFα), Interferon-gamma (IFNƴ), Interleukin-6 (IL-6), Interleukin-1 beta (IL-1β), which marks cytokine storm formation. To be precise, dysregulated balance can impede or increase susceptibility to pathogens. Pathogens have the ability hijack host system by interfering with host's chromatin architecture for their survival replication cell. Cytokines, particularly IL-6, Interleukin-17 (IL-17), Interleukin-23 (IL-23), play key role orchestrating innate responses shaping adaptive immunity. Understanding response epigenetic modification maintain structural aspects IL-17, IL-23 illuminating novel therapeutic regimen treat infectious diseases. this review, light shed on how orchestration regulation facilitates homeostasis.

Language: Английский

Citations

1
Peripheral Blood Biomarkers Predicting the Efficacy of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer: A Retrospective Study DOI

Jinshan Yan,

Xin Li, Hong Xiao

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: July 2, 2024

Abstract Introduction: Non-small cell lung cancer (NSCLC) leads to substantial challenges in treatment owing its diverse histological and molecular characteristics. Immune checkpoint inhibitors (ICIs) have revolutionized the management of NSCLC. Nevertheless, there exist limitations utilizing biomarkers, like PD-L1 expression for predicting efficacy ICIs, necessitating novel biomarkers. Methods We investigated relationship between peripheral blood T subsets, cytokines, ICIs patients who received as their first-line pathologically confirmed locally advanced or metastatic NSCLCs. Propensity score matching (PSM) was employed match individuals response non-response groups. Subsequently, lymphocyte profiles cytokine subsets were measured using flow cytometry. Mann-Whitney Kruskal-Wallis tests used intergroup analysis before, after, during treatment. Log-rank regression Cox models analyze survival conduct multivariate analysis, respectively. Results Between July 1, 2021, December 31, 2023, 470 with clinical stage IIIB IV After applying inclusion criteria, a post-propensity score-matching performed on 102 patients. The median progression-free (PFS) 14.30 months. These included activated CD4+ cells (HLA-DR+)/CD4% (P = 0.0170), memory CD8+ cells/CD8% 0.0115), (CD38+)/CD8% 0.0020), (HLA-DR+)/CD8% < 0.0001). Changes levels before after indicated that IL-6 showed downward trend responder group. Additionally, our revealed an increased ratio (CD38+)/CD8% (average PFS: 22.207m vs. 15.474m) decreased CD8 + (HLA-DR+)/CD8% (mean 17.729m 25.662m) are associated longer PFS. Multivariate unveiled alterations abundance independent prognostic factors PFS Conclusions This study emphasizes significance biomarkers Activated CD8+T (CD38+) represent promising biomarker providing insights into personalized strategies. Further prospective studies warranted validate findings improve outcome

Language: Английский

Citations

0
ANCA-associated vasculitis and lung cancer: an immunological perspective DOI Creative Commons
Longzhao Li,

Jun Teng,

Na Kou

et al.

Clinical and Experimental Medicine, Journal Year: 2024, Volume and Issue: 24(1)

Published: Sept. 4, 2024

Language: Английский

Citations

0
Leveraging Evolutionary Immunology in Interleukin-6 and Interleukin-17 Signaling for Lung Cancer Therapeutics DOI

Riya Khilwani,

Shailza Singh

ACS Pharmacology & Translational Science, Journal Year: 2024, Volume and Issue: 7(12), P. 3658 - 3670

Published: Nov. 22, 2024

Lung cancer is among the most common instances of subtypes and associated with high mortality rates. Due to availability fewer therapies delayed clinical investigations, number incidences rising dramatically. This possibly an effect immune modulations chemotherapeutic drugs that raises resistance. Among list, IL-6 IL-17 are host-derived paradoxical effectors attune responses in malignant lung cells. Their excessive release cytokine milieu stabilizes immunosuppressive phenotypes, resulting cellular perturbations. During tumor development, significance these molecules reflected their potential regulate oncogenesis by initiating a myriad signaling events influence growth metastatic ability benign Moreover, transactivation contributes antiapoptotic mechanisms favors cell survival via constitutive expression immunoregulatory molecules. Co-evolution gene duplication could be major drivers behind evolution, which have prompted generic changes and, hence, additive effect. The evolutionary model statistical analysis provide evidence about cytokines ancestral relationships site-specific conservation, more convincing as both share cysteine-knot-like structures important maintaining structural integrity. Funneling through findings help find residues serve catalytic role functioning. Designing peptides or subunit vaccine formulations against those conserved aid combating pathogenesis.

Language: Английский

Citations

0